This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
GEHC Expands Carilion Tie to Enhance Patient Care Across Virginia
by Zacks Equity Research
GE HealthCare expands its Carilion Clinic collaboration with AAMP and Encompass to improve equipment management and operational efficiency across Virginia.
WSTPositive Net Change GMEDNegative Net Change BDSXPositive Net Change GEHCNegative Net Change
medical medical-devices
QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use
by Zacks Equity Research
QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.
ISRGPositive Net Change QGENNegative Net Change WSTPositive Net Change GMEDNegative Net Change
medical medical-devices
ISRG's Capital Placement Surge: Demand Strength or Upgrade Cycle Peak?
by Indrajit Bandyopadhyay
ISRG placed 431 da Vinci systems in Q1 2026, but rising trade-ins and leasing growth raise questions about whether demand is structural or upgrade-driven.
ISRGPositive Net Change STXSNo Net Change GMEDNegative Net Change
medical medical-devices
Should You Buy Usio Inc (USIO) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
USIONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Polaris Inc (PII) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PIINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Continue to Hold PAHC Stock in Your Portfolio?
by Zacks Equity Research
Phibro Animal Health gains from Animal Health strength and Zoetis MFA integration, but macro and FX headwinds remain as the stock rises 27.6% over the past year.
ALGNPositive Net Change IARTNegative Net Change GMEDNegative Net Change PAHCPositive Net Change
medical medical-devices
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
Stryker faces cyberattack fallout, but strong procedure demand, record Mako adoption and global expansion continue to support long-term growth.
SYKNegative Net Change ALGNPositive Net Change CAHPositive Net Change WSTPositive Net Change
medical medical-devices
Veeva Expands Safety Suite Footprint With UCB Pharmacovigilance Deal
by Zacks Equity Research
VEEV's UCB pharmacovigilance deal expands Safety Suite adoption, supporting automation, compliance and long-term growth opportunities.
ISRGPositive Net Change WSTPositive Net Change GMEDNegative Net Change VEEVPositive Net Change
medical medical-devices
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
by Zacks Equity Research
HQY benefits from strong HSA growth, AI-driven automation and solid first-quarter fiscal 2027 results despite data security risks.
ISRGPositive Net Change WSTPositive Net Change GMEDNegative Net Change HQYNegative Net Change
medical medical-devices
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
by Zacks Equity Research
OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.
WSTPositive Net Change GMEDNegative Net Change BDSXPositive Net Change OGNPositive Net Change
medical medical-devices